Search Results 1291-1300 of 18545 for hepatitis

  1. David M.H. Chascsa, M.D. - Doctors and Medical Staff - Mayo Clinic

    Viral hepatitis; Autoimmune and cholestatic liver disease including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC); Liver cancer ...

  2. A Study to Evaluate Trifluridine/Tipiracil Combined with Bevacizumab vs Trifluridine/Tipiracil to Treat Patients with Refractory Metastatic Colorectal Cancer - Mayo Clinic

    Known Hepatitis B or Hepatitis C Virus infection. Known carriers of HIV antibodies. Confirmed uncontrolled arterial hypertension (defined as systolic blood ...

  3. Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence after Liver Transplantation - Mayo Clinic

    Participation eligibility · Presence of ischemic cholangiopathy which can mimic rPSC · LT performed for primary biliary cholangitis or autoimmune hepatitis, or ...

  4. Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH - Mayo Clinic

    Exclusion of other causes of liver disease including viral hepatitis and alcoholic liver disease ... Positive for hepatitis C virus (HCV) RNA; Positive for HBsAg ...

  5. Insulin glargine-yfgn, recombinant (subcutaneous route) - Mayo Clinic

    Sharing needles or pens can result in transmission of hepatitis viruses, HIV, or other bloodborne illnesses. Your doctor will want to check your progress at ...

  6. Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients - Mayo Clinic

    Be undergoing treatment for acute or chronic hepatitis C. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for ...

  7. A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) - Mayo Clinic

    on anti-retroviral therapy (ART). - Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) ...

  8. Tucatinib and Trastuzumab for Patients with HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

    Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months).

  9. Evaluate REC-4881 in Patients With FAP (TUPELO) - Mayo Clinic

    Active or known HIV, hepatitis B or hepatitis C infections. 21. Has a severe or uncontrolled medical condition. 22. Use of strong BCRP or MRP2 inhibitors ...

  10. A Study of the Safety and Effectiveness of Nivolumab for the Treatment of Advanced Non-Small Cell Lung Cancer - Mayo Clinic

    Active or chronic infection of hepatitis B virus or hepatitis C. Participating Mayo Clinic locations. Study statuses change often. Please contact the study ...